Research Article

The Clinical Efficacy and Safety of Gumiganghwal-Tang in Knee Osteoarthritis: A Phase II Randomized Double Blind Placebo Controlled Study

Table 2

Demographic data and baseline characteristics.

CharacteristicsGMGHT group (n= 70)Placebo group (n= 73)p value

Sex (female), n (%)67 (95.7)62 (84.9)0.05
Age58.5 (8.7)59.7 (7.5)0.41
Height (m)1.57 (0.06)1.57 (0.07)0.77
Body weight59.1 (6.7)62.3 (9.3)0.02
BMI (kg/m2)23.9 (2.2)25.2 (4.2)0.02
Duration of symptomatic OA (months)51.7 (54.3)61.4 (63.3)0.33
Radiographic findings (Kellgren and Lawrence X-ray grade )
 Grade 2, n (%)45 (64.3)42 (57.5)0.43
 Grade 3, n (%)20 (28.6)28 (38.4)
 Grade 4, n (%)5 (7.1)3 (4.1)
Patient’s global assessment (0-100 VAS)65.1 (17.5)69.2 (13.0)0.13
Patient’s pain assessment (0-100 VAS)68.4 (11.5)71.0 (13.6)0.22
Physician’s global assessment (0-100 VAS)65.7 (11.8)68.1 (13.4)0.28
WOMAC score
 Pain11.1 (2.3)11.3 (3.0)0.70
 Stiffness4.7 (1.3)4.3 (1.4)0.17
 Function39.6 (10.0)40.5 (9.6)0.55
 Total55.4 (12.7)56.2 (12.9)0.70

Values are presented as numbers (%) or mean (SD) unless otherwise stated.
BMI: body mass index, GMGHT: Gumiganghwal-tang, OA: osteoarthritis, SD: standard deviation, VAS: visual analog scale, WOMAC: the Western Ontario and McMaster Universities Arthritis Index.